Clinical trials: Depressive State
Depressive Disorder, Depression
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Pyxis (NCT01360645)
- Testing
- OPC-34712 + ADT
- Where
- 57 sites in United States, Canada and 3 more
- Volunteers
- 826 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depression, Anxiety
A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health
Ketamine-Assisted Psychotherapy (KAP) is a relatively new approach for the treatment of mental health issues, which involves the combination of ketamine, a dissociative anaesthetic with psychedelic properties, and psychotherapy…
- Conditions
- Depression, Anxiety, Post Traumatic Stress Disorder
- Trial name
- NCT05604794
- Testing
- Ketamine-Assisted Psychotherapy (KAP)
- Where
- 11 sites in United States, Canada
- Volunteers
- 1,806 people
- Sponsor
- Field Trip Health
Unipolar Depression, Major Depressive Disorder (MDD)
Validation of EmoDTx as a Digital Endpoint for Mood Monitoring in Adult Patients Suffering From Unipolar Depression
The aim of this study is to validate the EmoDTx as a digital tool for mood monitoring in adult patients with unipolar depression. The study is prospective, multicenter, and observational, with a single-arm approach.
- Conditions
- Unipolar Depression, Major Depressive Disorder (MDD), Depression
- Trial name
- EMC2FR (NCT06860165)
- Where
- 2 sites in France
- Volunteers
- 98 people
- Sponsor
- Emobot
Healthy Volunteers
Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety
This Phase I/II clinical trial investigates the safety, tolerability, and potential therapeutic benefits of a novel sublingual formulation of 5-MeO-DMT.
- Trial name
- 5-MeO-DMT (NCT06816667)
- Testing
- BMND08, Brain electrical activity monitor, Pharmacokinetic Study of Sublingually Administered Psychoactive Substance
- Where
- Argentina
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Biomind Labs Inc.
Schizophrenia, Psychotic Disorders
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
This is a randomized, single-dose, open-label, parallel-group study. Patients will undergo the screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05321602
- Testing
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid
- Where
- 9 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Unipolar Depression
Validation of the Spanish Version of the Clinically Useful Depression Outcome Scale (CUDOS) Scale
The Clinically Useful Depression Outcome Scale (CUDOS) is a brief, self-administered instrument that not only evaluates depressive symptoms but also both functioning and quality of life.
- Trial name
- CUDOS (NCT01360307)
- Where
- 17 sites in Spain
- Volunteers
- 330 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder
This is an outpatient study to evaluate the safety, and efficacy of RGH-188 as an add-on therapy to standard antidepressants in patients who did not respond to previous antidepressant therapy.
- Trial name
- NCT00854100
- Testing
- Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d)
- Where
- 41 sites in United States
- Volunteers
- 231 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder, Generalized Anxiety Disorder
Digital Therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)
Participants with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) will use a prescribed digital therapeutic for 8-10 weeks, and will complete depression and anxiety measures during this time.
- Trial name
- NCT05016050
- Testing
- HPDT-DA-013
- Where
- United States
- Volunteers
- 367 people
- Sponsor
- Happify Inc.
Depression - Major Depressive Disorder, Cognition Disorders in Old Age
Real-world Clinical Response to Trazodone in Italy, Poland, and Romania
TRACOMDD study is a study with the intention to describe the real-world use of trazodone and the clinical response in a sub-group of patients affected by Major Depressive Disorder and Mild Cognitive impairment, by collecting data…
- Trial name
- NCT07377682
- Where
- Poland
- Volunteers
- 120 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Depression
Internet-Based Treatment of Depression: Comparing Guided With Unguided Self-Help
The study is a randomized controlled trial and to compare the benefits of a 10-week web-based unguided self-help treatment with the same intervention complemented with weekly therapist support via e-mail.
- Trial name
- NCT04428450
- Testing
- Deprexis
- Volunteers
- 76 people
- Sponsor
- Gaia AG
Multiple Sclerosis
Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis
Fampyra, a voltage-dependent potassium channel blocker, is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7).
- Trial name
- FAMILY (NCT03164018)
- Testing
- Fampridine
- Where
- Greece
- Volunteers
- 111 people
- Sponsor
- Genesis Pharma CNS & Specialty
Parkinson Disease
The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease
Documentation of the effect of SIFROL® on tremor and depression as well as its tolerability in ambulatory patients suffering from idiopathic Parkinson's disease under routine conditions
- Trial name
- NCT02231294
- Testing
- Sifrol®
- Volunteers
- 1,464 people
- Sponsor
- Boehringer Ingelheim
Respiratory Depression
PRediction of Opioid-induced Respiratory Depression In Patients Monitored by capnoGraphY
PRODIGY is a prospective, multi-center, post-market, international cohort study. The primary objective of this study is to derive a score to identify subjects at risk to have respiratory depression (RD) episodes in patients…
- Trial name
- PRODIGY (NCT02811302)
- Testing
- Capnostream Monitor
- Where
- 16 sites in United States, France and 5 more
- Volunteers
- 1,495 people
- Sponsor
- Medtronic - MITG
Major Depressive Disorder
Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine
The purpose of the study is to describe the association/correlation between change in patient-reported cognitive symptoms and work productivity in gainfully employed patients receiving vortioxetine for a Major Depressive Episode…
- Trial name
- AtWoRC (NCT02332954)
- Testing
- vortioxetine
- Where
- 26 sites in Canada
- Volunteers
- 226 people
- Sponsor
- Lundbeck Canada Inc.
Depressive Symptoms, Urinary Incontinence
BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women
The goal of this clinical trial is to evaluate if the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices is able to improve depressive symptoms and sexual function in women who are perimenopausal or…
- Conditions
- Depressive Symptoms, Urinary Incontinence, Sexual Dysfunction
- Trial name
- NCT07413705
- Testing
- EXOMIND (BTL-699-2) Active Treatment, EMSELLA (HPM-6000UF) ActiveTreatment
- Where
- 3 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- BTL Industries Ltd.
Depression
Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression
Medtronic, Inc. sponsored an investigational study of the Reclaim™ Deep Brain Stimulation (DBS) System in people that have treatment-resistant depression.
- Trial name
- NCT00837486
- Testing
- Reclaim™ DBS System
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- MedtronicNeuro
Pain, Depression
Study Evaluating Rhapsody Registry in Patients With Depression and Anxiety
The purpose of this study is to assess the prevalence of Major Depression and/or Anxiety Disorder in patients consulting the General Practitioner with acute or chronic painful physical symptoms and to identify risk factors.
- Conditions
- Pain, Depression, Anxiety Disorder
- Trial name
- NCT00241397
- Where
- 91 sites in Belgium
- Volunteers
- 2,560 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depression Bipolar
Study Evaluating Bifeprunox in Bipolar Depression
The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of Bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
- Trial name
- NCT00245973
- Testing
- Bifeprunox
- Where
- 40 sites in United States
- Volunteers
- 380 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy of switching adult participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to flexibly dosed intranasal…
- Trial name
- NCT03434041
- Testing
- Esketamine 56 mg, Esketamine 84 mg, Duloxetine (Oral Antidepressant)
- Where
- 30 sites in United States, China
- Volunteers
- 252 people
- Sponsor
- Janssen Research & Development, LLC
Restless Legs Syndrome, Depression
Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances
The primary objective of this study is to determine the efficacy of pramipexole 0.125 mg to 0.75 mg daily versus placebo on RLS symptoms and on associated mood disturbances and depressive symptoms, after 12 weeks of treatment
- Trial name
- NCT00356096
- Testing
- pramipexole
- Where
- 54 sites in Finland, France and 7 more
- Volunteers
- 404 people
- Sponsor
- Boehringer Ingelheim